

1

2 **Effectiveness of Psychological and/or Educational**
3 **Interventions in the Prevention of Anxiety**
4 **A Systematic Review, Meta-analysis and Meta-regression**

5 Patricia Moreno-Peral, PhD^{1,2,3}

6 Sonia Conejo-Cerón^{1,2,3}

7 Maria Rubio-Valera, PhD^{4,5,6}

8 Anna Fernández, PhD^{5,7}

9 Desirée Navas-Campaña, PhD^{1,2,3}

10 Alberto Rodríguez-Morejón, PhD^{2,3,8}

11 Emma Motrico, PhD^{2,9}

12 «DT1: Alina Rigabert^{9»}

13 Juan de Dios Luna, PhD^{2,10}

14 Carlos Martín-Pérez, MD, PhD^{2,11}

15 Antonina Rodríguez-Bayón, MD, PhD^{2,12}

16 María Isabel Ballesta-Rodríguez, MD, PhD^{2,13}

17 Juan Vicente Luciano, PhD^{2,4,14}

1 Juan Ángel Bellón, MD, PhD^{1,2,3,15,16}

2 ¹Research Unit, Primary Care District of Málaga-Guadalhorce, Málaga,
3 Spain

4 ²Prevention and Health Promotion Research Network (~~redIAPP~~), Málaga,
5 Spain

6 ³Institute of Biomedical Research in Malaga (~~IBIMA~~), Málaga, Spain

7 ⁴Sant Joan de Déu Research Foundation, Barcelona, Spain

8 ⁵Network for Biomedical Research on Epidemiology and Public Health,

9 «DT2: CIBERESP

10 ⁶School of Pharmacy, University of Barcelona, Barcelona, Spain

11 ⁷Service of Community Health, Public Health Agency of Barcelona (~~ASPB~~),
12 Barcelona, Spain

13 ⁸Department of Personality, Evaluation, and Psychological Treatment,
14 Universidad de Málaga, Málaga, Spain

15 ⁹Department of Psychology, University Loyola Andalucía, Seville, Spain

16 ¹⁰Department of Biostatistics, University of Granada, Granada, Spain

17 ¹¹Primary Care Center of Marquesado, Área Nordeste de Granada, Granada,
18 Spain

1 ¹²Primary Care Center of San José, Linares, Jaén, Spain

2 ¹³Primary Care Center of Federico del Castillo, Jaén, Spain

3 ¹⁴Teaching, Research & Innovation Unit, Parc Sanitari Sant Joan de Déu, St
4 Boi de Llobregat, Spain

5 ¹⁵Primary Care Center of El Palo, Málaga, Spain

6 ¹⁶Department of Preventive Medicine, Public Health and Psychiatry,
7 University of Malaga, Málaga, Spain

8 **Question:** Are psychological and/or educational preventive interventions for
9 anxiety effective in ~~all type of~~ varied populations?

10 **Findings:** This systematic review and meta-analysis of 29 randomized
11 ~~controlled~~ clinical trials (36 comparisons) including 10 430 patients from 11
12 countries on 4 continents showed a small, but statistically significant, effect
13 size of psychological and/or educational preventive interventions for
14 anxiety. Sensitivity analyses and adjustment for publication bias confirmed
15 that the results were robust.

16 **Meaning:** Although the ~~effectiveness~~ benefit of psychological and/or
17 educational interventions in the prevention of anxiety is modest, the results
18 obtained suggest that psychological and/or educational preventive
19 interventions for anxiety should be further developed and implemented.

1 **Importance** No systematic reviews or meta-analyses have been conducted
2 to assess the effectiveness of preventive psychological and/or educational
3 interventions for anxiety in ~~all types of~~varied populations.

4 **Objective** To evaluate the effectiveness of preventive psychological and/or
5 educational interventions for anxiety in ~~all~~varied population types.

6 **Data Sources** A systematic review and meta-analysis was conducted based
7 on literature searches ~~on~~of MEDLINE, PsycINFO, ~~WOS~~Web of Science,
8 EMBASE, OpenGrey, Cochrane Central Register of Controlled Trials, and
9 other sources from inception ~~up~~ to March 7, 2017.

10 **Study Selection** A search was performed of ~~1~~ 1 zed ~~controlled-clinical~~
11 trials assessing the effectiveness of preventive psychological and/or
12 educational interventions for anxiety in ~~all types of~~varying populations free
13 of anxiety at baseline (~~as measured using validated instruments~~). There was
14 no setting or language restriction. Eligibility criteria assessment was
15 conducted by ~~two~~2 independent investigators.

16 **Data Extraction and Synthesis** Data extraction and assessment of risk of
17 bias (Cochrane Collaboration's tool) were performed by ~~two~~2 independent
18 investigators. Pooled standardized mean differences (SMDs) were

1 calculated, using random-effect models. Heterogeneity was explored by
2 random-effects meta-regression.

3 **Main Outcomes and Measures** Incidence of new cases of anxiety
4 disorders or reduction of anxiety symptoms as measured by validated
5 instruments.

6 **Results** Of the 3273 abstracts reviewed, 131 were selected for full-text
7 review, and 29 met [the](#) inclusion criteria, representing 10,430 patients from
8 11 countries on 4 continents. Meta-analysis calculations were based on 36
9 comparisons. The pooled SMD was -0.31 (95% CI, -0.40 to -0.21 ; $P <$
10 $.001$) and heterogeneity was substantial ($I^2 = 61.1\%$; 95% CI, **DT3:** 44%

11 to 73% There was evidence of publication bias, but the effect size barely
12 varied after adjustment (**DT4:** SMD, -0.27 ; 95% CI, -0.37 to -0.17 ; $P <$
13 $.001$) Sensitivity analyses confirmed the robustness of effect size results.

14 A meta-regression including ~~five~~ 5 variables explained 99.6% of between-
15 study variability, revealing an association between higher SMD, waiting list
16 (comparator), and a lower sample size. No association was observed with
17 risk of bias, family physician providing intervention, ~~(provider)~~ and use of
18 standardized interviews as outcomes.

1 **Conclusions and Relevance** Psychological and/or educational
2 interventions had a small, but statistically significant, benefit for anxiety
3 prevention in all ~~types of~~ populations evaluated. Although more studies with
4 larger samples and active comparators are needed, these findings suggest
5 that anxiety prevention programs should be further developed and
6 implemented.

7 **Introduction**

8 The annual prevalence of anxiety disorders is 6.7% in the general
9 population.¹ The burden of disease in terms of years lived with disability
10 attributable to anxiety disorders increased by 14.8% (relative increase)
11 between 2005 and 2015, ranking ninth in the world and eighth in high-
12 income countries.² Among mental and substance use disorders, anxiety
13 ranked second in the world.³ Although there are effective treatments for
14 anxiety disorders,⁴⁻⁶ not all persons with anxiety receive the appropriate
15 treatment,⁷ and cost-effectiveness studies suggest that treatment alone is not
16 sufficient to eliminate the disease burden attributable to anxiety disorders.⁸
17 ~~Besides,~~ An additional way to reduce the burden of anxiety disorders is to
18 ~~reduce~~ lower the incidence of new cases, which can be achieved through
19 prevention rather than treatment.

1 Previous systematic reviews or meta-analyses ~~on~~of the prevention of
2 anxiety have been mainly undertaken in children and/or adolescents.⁹⁻¹³ In
3 adults, studies have ~~been~~traditionally focused on specific anxiety disorders,
4 such as posttraumatic stress disorder ~~(PTSD)~~.^{14,15} ~~Only a~~One meta-analysis¹⁶
5 assessed the prevention of anxiety in the general population, although it was
6 centered on specific cognitive-behavioral interventions. To the best of our
7 knowledge, no systematic review or meta-analysis has been performed ~~so far~~
8 on the effectiveness of psychological and/or educational interventions in
9 preventing anxiety ~~in all~~several types of populations. The aim of the present
10 systematic review and meta-analysis was to evaluate the effectiveness of
11 psychological and/or educational interventions in preventing anxiety in
12 varied populations.

13

14

15

16

17

1 **Methods**

2 We followed PRISMA (~~Preferred Reporting Items for Systematic~~
3 ~~Reviews and Meta-analyses~~) guidelines for reporting systematic reviews and
4 meta-analyses.¹⁷ The protocol of this systematic review was previously
5 registered at the International Prospective Register ~~o~~Of Systematic Reviews
6 (~~PROSPERO registration number: CRD42016049404~~). **DT5:** ~~X~~

7 **Search Strategies**

8 We systematically searched ~~five~~5 electronic databases, including
9 PubMed, PsycINFO, Embase, ~~WOS~~Web of Science, OpenGrey (System for
10 Information on Grey Literature in Europe), and CENTRAL (Cochrane
11 Central Register of Controlled Trials) from inception to March 7, 2017. No
12 date or language restrictions were imposed. This search strategy was
13 complemented with hand searching of reference lists ~~on~~in articles and other
14 reviews on this topic. In addition, experts in the field were contacted and
15 asked to complete the list of selected publications. Databases were searched
16 separately by ~~two~~2 reviewers (P.M.-P. and S.C.-C.). The specific search
17 strategies used are described in the eAppendix in the Supplement.

Eligibility Criteria

1
2 We selected [randomized clinical trials \(RCTs\)](#) because they are the
3 ~~gold~~ standard for clinical trials.¹⁸ We focused on educational and/or
4 psychological interventions. The former simply provide information about
5 anxiety through lectures or fact sheets, whereas psychological interventions
6 attempt to change how people think, using a variety of strategies (eg,
7 cognitive behavioral or interpersonal therapy). ~~RCTs~~ [Randomized clinical](#)
8 [trials](#) based on medication or physical interventions (eg, sports) were
9 excluded. The comparators allowed were care-as-usual, no intervention,
10 **«DT6:** [waiting list](#), [attention control](#). To separate the effectiveness of
11 prevention from that of therapies, baseline anxiety was required to have been
12 discarded through standardized interviews (eg, **«DT7:SCID»**), validated
13 self-reports with standard cutoff points (eg, **«DT8:BAI-II»**), or diagnosis
14 by a mental health specialist. Outcomes included the incidence of new cases
15 of any *DSM-IV* anxiety disorder and/or the reduction of anxiety symptoms.
16 Outcomes were required to have been measured by standardized interviews
17 or validated symptom scales. [Posttraumatic stress disorder](#) ~~PTSD~~ was
18 excluded because, in this case, it is difficult to separate treatment from

1 prevention.¹⁹ Participants could have any demographic characteristic (eg,
2 age, sex, ~~etc.~~) and all settings and languages were considered.

3 **Selection of Studies**

4 Titles and abstracts were reviewed independently by ~~two~~ 2 reviewers
5 authors (P.M.-P. and S.C.-C.), who used the ~~criteria~~ above mentioned criteria
6 to determine study eligibility. The ~~F~~ full text of potentially relevant studies
7 was reviewed for final inclusion. All discrepancies were resolved by
8 consensus with a third study reviewer (M.R.-V. or A.F.). The degree of
9 agreement between ~~PMP and SCC~~ the initial reviewers was good (Cohen's ~~s~~ k
10 ~~= kappa~~ 0.74; 95% CI, 0.60-0.89).²⁰

11 **Data Extraction**

12 Data extracted from each study were recorded in an evidence table.
13 Two independent reviewers (P.M.-P. and S.C.-C.) collected data from
14 primary studies. Any discrepancies were solved by consensus between the
15 reviewers. When necessary information was not reported in the study, the
16 authors of the original article were contacted for further details.

17 **Assessing the Risk of Bias**

18 We used the Cochrane Collaboration ~~R~~ risk of bias ~~2~~ tool to assess the
19 quality of the studies included.²¹ All of the studies included were assessed

1 and any disagreements were resolved by ~~two~~2 independent reviewers (P.M.-
2 P. and S.C.-C.). ~~Disagreements were solved by the two raters.~~ The level of
3 agreement was good (intraclass correlation coefficient, 0.83; 95% CI, 0.77-
4 0.87).²²

5 **Statistical Analyses**

6 ~~We used Comprehensive Meta-Analysis (CMA version 3.0) and~~
7 ~~STATA Release 14.2 to perform analyses.~~

8 When the outcome was differences in anxiety symptoms between
9 intervention and control groups, means ~~and standard deviations~~(SDs) for
10 each arm were extracted. ~~Then, for each RCT w~~We then calculated
11 standardized mean differences (SMDs) for each RCT by estimating the
12 mean SMD at different follow-up times. The pooled SMDs for all RCTs and
13 ~~its~~their 95% ~~confidence interval~~(CIs) were estimated. Negative SMDs
14 represented an improvement in the reduction of anxiety symptoms~~atology~~ in
15 the intervention group. If only new cases of anxiety were reported (incidence
16 of anxiety), **«DT9: Comprehensive Meta-Analysis (CMA),»>>** version 3.0
17 ~~CMA~~ was used to obtain the equivalent SMDs. Cohen**«DT10: offered**
18 the following guidelines for interpreting the magnitude of this effect size:
19 “an SMD of 0.2 is considered as indicating a low effect; SMD of 0.5

1 indicates a moderate effect and 0.8 a large effect.” «DT11: ²³» We have
2 inflated the ~~standard errors~~SEs of the nested comparisons in the same RCT
3 following the suggestions of Cates.²⁴ We selected the random-effects model
4 for ~~our~~the study; under the assumption that the studies included in ~~our~~the
5 meta-analysis were performed in a variety of ‘populations’ that may differ
6 from each other.²¹

7 Statistical heterogeneity was evaluated using the I^2 statistic, where a
8 value of 0% to -40% might ~~be~~indicate not important heterogeneity; 30% to
9 -60% , moderate; 50% to -90% , substantial; and 75% to -100% ,
10 considerable.²¹ In addition, we calculated the Q statistic and its P value.

11 To detect publication bias, a funnel plot was examined by visual
12 inspection and the Duval and Tweedie’s²⁵ trim-and-fill procedure, which is a
13 test of symmetry of the funnel plot.²⁵ This procedure yields an adjusted
14 pooled effect size after accounting for missing studies due to publication
15 bias. We also performed «DT12: Begg and Mazumdar rank correlation
16 and the Egger’s test

17 Since the SMD could differ at varying follow-up times, we also
18 conducted sensitivity analyses at first and last follow-ups. Sensitivity
19 analyses also included fixed effects and; Hedges’ g , and excluding some

1 RCTs from analysis (those ~~which~~ that caused the greatest increase in
2 heterogeneity and those ~~which~~ that measured anxiety as a secondary
3 outcome).

4 We used a mixed-effects model for sub-group analyses according to
5 the type of prevention, type of outcome measure (symptoms scale vs
6 standardized diagnostic interview), type of anxiety, country, population age,
7 setting, comparator, ~~provider~~ (the professional delivering the intervention),
8 intervention orientation, type of intervention, intervention format, number of
9 sessions, follow-up, sample size, and risk of bias.

10 Meta-regression was performed to explain the between-trial
11 heterogeneity observed. We forced ~~two~~ 2 quantitative variables—risk of bias
12 and sample size—in the meta-regression models for adjustment. The former
13 is related to the quality of the RCTs and the latter to publication bias. Of the
14 remaining covariables considered for subgroup analysis, only ~~a~~ 1 covariable
15 was introduced in each new model. The final model was composed of the
16 ~~two~~ 2 forced quantitative variables and dummy covariables with a
17 significance level of $P < .15$ that were not removed from the model due to
18 collinearity. We used the Knapp ~~and~~ & Hartung method²⁶ to estimate
19 ~~standard error~~ SE and ~~confidence intervals~~ 95% CIs. We also used a Higgins
20 ~~and~~ & Thompson²⁷ permutation test approach to calculate P values, taking

1 into account multiplicity adjustment **DT13:** [Monte Carlo approach; 20](#)
2 [000 permutations](#) [we used CMA, version 3.0 and Stata, version 14.2](#)
3 [\(StataCorp\) to perform analyses.](#)

4

5

Results

6

Search Results

7

8

9

A total of 3273 abstracts were reviewed. ~~Next~~ [Of these](#), 131 articles were included for full-text review. ~~Finally and~~, 29 RCTs met the inclusion criteria of ~~our~~ [the](#) meta-analysis (Figure 1).²⁸⁻⁵⁷

10

Characteristics of Included Studies

11

12

13

14

The characteristics of the 29 RCTs included are described in ~~the~~ eTable 1 in the Supplement. ~~Most~~ [Twenty](#) studies (~~20~~) were published in or after 2010, and only ~~three~~ [3](#) RCTs were published before 2005. Seven RCTs were conducted in the ~~US~~ [United States](#).

15

16

17

A total of 10 430 patients were enrolled. Sample sizes ranged from 24 to 2998 (median, ~~=~~ 165). A total of 9 RCTs included adults (from 18 to 65 years), 9 included children or adolescents, 4 were performed in older adults,

1 6 in adults and elderly individuals, and 1 in both; adults and children.

2 Settings included school or university in 12 RCTs.

3 Interventions were based on the principle of cognitive behavioral
4 therapy (~~CBT~~) in 25 RCTs, whereas 4 RCTs were based on other types of
5 interventions (2 psychoeducational, 1 acceptance and commitment therapy,
6 and 1 biopsychosocial). Interventions were delivered in individual format in
7 14 RCTs. Four RCTs included interventions with a guided self-help format
8 (computerized). The number of sessions ranged from ~~one~~ 1 to 12 (median, ~~=~~
9 8). The comparator ~~employed~~ used was care-as-usual in 13 RCTs.

10 Interventions were conducted by a mental health specialist in 13 RCTs.

11 Follow-up periods ranged from 7 weeks to 60 months (median, ~~=~~ 12
12 months). The duration of follow-up exceeded 12 months in ~~six~~ 6 RCTs.

13 Indicated, selective, and universal prevention were evaluated in 11,
14 10, and 8 RCTs, respectively. With respect to outcomes, 10 RCTs measured
15 the reduction in anxiety symptoms and; 10 determined the incidence of
16 anxiety disorders; ~~and~~ 9 RCTs measured both reduction of symptoms and
17 incidence.

Risk of Bias in Included Studies

The risk of bias for each study is ~~shown~~reported in eTable 2 in the Supplement. Eight RCTs had a low risk ~~of bias~~ (≤ 4 points), 9 had a moderate risk (5-6 points), and 12 had a high risk ~~of bias~~ (≥ 7 points)of bias.

Effectiveness of the Interventions to Prevent Anxiety

Meta-analysis calculations were based on 36 comparisons performed in 29 RCTs (eTable 3 in the Supplement). The pooled SMD was -0.3105 (95% CI, -0.400 to -0.2109 ; $P < .001$), and the equivalent pooled odds ratio (OR) was 0.57 (95% CI, 0.48 to 0.68; $P < .001$), with substantial heterogeneity ($I^2 = 61.1\%$; $Q_{35} = 90.130$; ~~$df(Q) = 35$~~ ; $P < .001$). This finding means that psychological and/or educational preventive interventions for anxiety had a small and statistically significant effect on anxiety prevention. Figure 2 shows the forest plot for the overall and individual effect sizes.

Publication Bias

Results of The Egger's (intercept, -1.30295 ; 95% CI, -2.2549 to -0.344 ; $P = .01$) and Begg's test ($Z = -2.40$; $P = .02$) tests indicated the presence of publication bias. The SMDs adjusted for publication bias according to Duval and Tweedie's trim-and-fill procedure barely decreased

1 (SMD, ~~-0.2768~~; 95% CI, ~~-0.3766~~ to ~~-0.171~~). The ~~F~~funnel plot is shown in
2 ~~the~~eFigure 1 in the Supplement.

3 **Sensitivity Analyses**

4 Sensitivity analyses are ~~shown-reported~~ in Table 1. The pooled SMDs
5 ~~searcely~~changed little with the first or last evaluation, the fixed-effect
6 model, or the Hedges g ; test when the RCT³⁸ that most increased
7 heterogeneity or the RCTs in which anxiety was a secondary outcome^{30,38,40}
8 were excluded.

9 **Subgroup Analyses**

10 **<DT14: Subgroup>>**analyses revealed differences in the
11 effectiveness of psychological and/or educational interventions depending
12 on the outcome measure, comparator, provider, sample size, risk of bias, and
13 follow-up (eTable 4 in the Supplement).

14 **Meta-Regression**

15 Meta-regression is ~~shown-reported~~ in Table 2. As many as 85.3% of
16 total variance was attributable to within-study variability, and the remaining
17 14.7% was attributable to between-study variability. In total, 99.6% of
18 between-study variance was explained by the ~~five-5~~ variables included in the
19 meta-regression model. There was a statistically significant association

1 between higher SMD ~~and~~ with a lower sample size, and when the
2 comparator was “waiting list”. There was no association between SMD and
3 risk of bias, type of outcome measure (standardized interview), and family
4 physician (~~provider~~ caregiver). Analysis of residuals showed a good fit of the
5 meta-regression model (eFigure 2 in the Supplement).

6 **Discussion**

7 **Summary**

8 We found that psychological and/or educational interventions are
9 effective in the prevention of anxiety. The overall effect size was small but
10 statistically significant. This result was derived from 29 RCTs (36
11 comparisons), ~~which~~ that included 10 430 patients from 11 countries on 4
12 continents. Sensitivity analyses and adjustment for publication bias
13 demonstrated that the overall effect size was robust. Heterogeneity was
14 substantial and ~~completely~~ explained by a model of meta-regression
15 including ~~five~~ 5 variables, 2 of which ~~two~~ had a statistically significant
16 association with effect size (waiting list and sample size), whereas the other
17 ~~three~~ 3 variables did not (risk of bias, family physician as ~~provider~~ caregiver,
18 and standardized interview as outcome).

Strengths

1
2 To the best of our knowledge, this is the first systematic review and
3 meta-analysis to examine the effectiveness of psychological and/or
4 educational interventions in the prevention of anxiety in ~~all~~-varied types of
5 populations. Our meta-analysis included~~s~~ a reasonable number of ~~RTCs~~
6 ~~RCTs~~ representing a large population of individuals with different
7 characteristics and from diverse settings. In addition, this study involved~~s~~ a
8 wide spectrum of interventions (any psychological and/or educational
9 intervention) for ~~all~~-most types of anxiety disorders (except ~~posttraumatic~~
10 ~~stress disorder~~PTSD) and implemented by a variety of professionals in
11 different settings. These aspects give the study a wide scope, which supports
12 its external validity. We ~~employed~~-used multiple complementary electronic
13 databases with supplementary hand searching. Thus, the variety of databases
14 ~~employed~~-utilized, combined with the ~~broad~~ range of search terms, ~~used~~
15 contributed to a highly sensitiv~~e~~ity search. ~~Besides~~In addition, the strict
16 inclusion criteria, ~~employed~~—by which ~~analyzing~~ only RCTs ~~including~~
17 ~~with~~ a study population free of anxiety at baseline, ~~—and that~~ allowed us to
18 distinguish prevention effectiveness from treatment effectiveness. Study
19 selection, data extraction, and risk of bias assessment were performed by
20 trained and independent reviewers, with good inter-observer reliability. We

1 performed sensitivity analyses and adjustment for publication bias, which
2 ~~results~~ support the robustness of the pooled SMDs. Finally, the meta-
3 regression model ~~completely~~ explained heterogeneity and enabled
4 adjustment for confounding biases and multiple comparisons.

5 Limitations

6 Our meta-analysis ~~had~~ has several limitations, ~~that must be taken into~~
7 ~~account~~. First, although most of the studies included had low-to-moderate
8 risk of bias (17 RCTs), 12 had a high risk of bias. Subgroup analysis showed
9 that the studies with a lower risk of bias had a tendency to report a ~~lower~~
10 smaller effect size (SMD, 0.15; 95% CI, ~~«DT15: 0.07»~~-0.23).
11 nevertheless, after adjusting for confounding biases, the meta-regression
12 model ~~clearly~~ showed that the risk of bias was not significant. ~~«DT16:~~
13 Second, the duration of follow-up exceeded 12 months in only 8 RCTs
14 ~~»~~which tended to report a lower effect size (SMD, 0.15; 95% CI, 0.01-0.29).
15 Although follow-up duration was ~~clearly~~ not significant when adjustment for
16 sample size and risk of bias was performed, firm conclusions about long-
17 term effectiveness cannot be drawn from our study. Third, the interventions
18 implemented in most of the RCTs included in ~~our~~ the meta-analysis were
19 aimed at preventing more than ~~one~~ 1 specific anxiety disorder (~~or simply~~

1 used non-specific anxiety symptoms as outcomes); therefore, no inferences
2 can be made about any specific anxiety disorder. Fourth, reduction of
3 anxiety symptoms (measured by scales) was the only outcome of 10 RCTs;
4 although the reliability and validity of scales are widely accepted,
5 standardized diagnostic interviews generally have greater validity.
6 Nevertheless, the reduction of anxiety symptoms is also useful as an
7 outcome because it has a positive and relevant ~~impact-effect~~ on quality of
8 life and cost.^{38,58} Another related aspect is that RCTs ~~where-in which~~
9 standardized diagnostic interviews were ~~employed-conducted~~ tended to
10 report a lower effect size («**DT17:** SMD, -0.18; 95% CI, 0.06-0.30»).

11 Again, adjustment for confounding biases and multiple comparisons in
12 meta-regression discarded any statistical significance. Fifth, evidence of
13 publication bias was found, which means that it is ~~quite~~-likely that some
14 RCTs with non-significant results ~~were~~-have not been published.
15 Nevertheless, this limitation does not seem relevant ~~as-because~~ the effect
16 size scarcely decreased after adjust~~menting~~ for publication bias. Sixth, we
17 cannot establish the superiority of ~~an-one~~ intervention over another (eg,
18 cognitive behavioral therapy CBT vs acceptance and commitment therapy)
19 because it was not within the scope of ~~our-the~~ study and we ~~purposely~~
20 excluded the few RCTs ~~where-this-in which these~~ types of comparisons were

1 made. Seventh, it is probable that the effect size of the anxiety prevention
2 that we obtained was ~~really~~ smaller ~~as~~ since it was increased by the use of
3 waiting list comparator and small samples. Finally, in some categories in
4 specific subgroup ~~-~~ analysis, the number of RCTs or comparisons was low; in
5 these cases (eg, ~~for~~ type of anxiety), the lack of statistical power prevents
6 ~~that~~ firm conclusions ~~are drawn~~.

7 **Comparison With Existing Literature**

8 The overall effect size obtained was small. Other meta-analyses on
9 anxiety prevention report similar SMDs (range 0.13-0.32),^{11-13,16} and the
10 same occurs with meta-analyses on the prevention of depression.⁵⁹⁻⁶¹

11 We ~~only~~ found statistically significant associations only for sample
12 size and waiting list as comparators when adjustment for confounding biases
13 and multiplicity testing were performed in meta-regression. A recent meta-
14 analysis on the effectiveness of cognitive behavioral therapy ~~CBT~~ for
15 anxiety disorders ~~(and major depression)~~ showed that ~~effects~~ responses were
16 large when the control condition was waiting list, but small to moderate
17 when it was care-as-usual or pill placebo.⁶² Similar results were found in a
18 network meta-analysis on the effectiveness of treatments for depression. The
19 authors suggest that waiting list can be a “nocebo” and may introduce
20 negative psychological expectations in the sense of ~~-~~waiting for the desired

1 active treatment², whereas patients allocated to ~~‘non-intervention~~ or usual
2 care² may more actively seek other treatments, either by themselves or by
3 others, for their ailment.⁶³ In a recent meta-analysis, subgroup analysis ~~on of~~
4 the prevention of anxiety in young people revealed that the studies ~~where in~~
5 which waiting list was ~~employed~~ used as a comparator tended to report a
6 significantly higher effect size; nevertheless, after adjustment~~ing~~ for
7 confounding factors in meta-regression, this tendency disappeared.¹¹ Zalta
8 ~~(2011)~~¹⁶ found no statistically significant differences between active and
9 non-active comparators in a meta-analysis, although, ~~in this meta-analysis,~~
10 waiting list was categorized within the ~~‘non-active’~~ category and no
11 adjustment for confounding factors was made.

12 Regarding sample size, effect sizes were smaller in the RCTs with
13 larger sample sizes after adjustment for confounding biases and multiple
14 comparisons were performed. This effect could be due to publication bias, as
15 evidenced in our meta-analysis, although its ~~impact~~ influence on the overall
16 effect size was minimal. Studies with small samples are more likely to
17 obtain negative results and not ~~to~~ be published; however, when they yield
18 statistically significant results, their effect sizes are higher.

19 Effect size tended to decrease when the outcomes were assessed using
20 standardized diagnostic interviews, although no statistically significant

1 associations were found in meta-regression. When RCTs had small samples,
2 ~~it was~~they were more likely to ~~get~~determine statistically significant effects
3 on anxiety prevention if symptom scales (difference of means) were
4 ~~employed~~utilized, ~~as~~ compared ~~to~~with structured interviews (comparison of
5 proportions). Furthermore, there was a negative correlation between risk of
6 bias and standardized interview as outcomes (~~Rho =~~ $\rho =$ -0.27). Therefore,
7 the loss of statistical significance between effect size and standardized
8 interview can be explained in part by adjustment for confounding factors
9 with the introduction of the variables ‘sample size’ and ‘risk of bias’ in the
10 meta-regression model. Adjustment for multiple comparisons also
11 contributed to the loss of significance.

12 Regarding the professional who delivered the intervention (~~the~~
13 ~~provider~~caregiver), effect sizes tended to increase when the ~~provider~~
14 caregiver was a family physician, but this effect was attenuated after
15 adjustments in meta-regression. The SMDs for family physician and mental
16 health specialist were similar, but the latter was removed from meta-
17 regression because of collinearity. Nevertheless, interventions were led by a
18 family physician in only ~~two~~2 RCTs and results should therefore be
19 interpreted with caution.

1 Subgroup analysis revealed statistically significant associations
2 between low risk of bias ~~and~~ with a lower effect size, and follow-up time
3 (SMDs higher in RCTs <6 months). However, this effect disappeared when
4 adjustment for confounding bias was performed. No relevant differences
5 were observed when the first (SMD₁ = 0.30) and last ~~evaluation~~ (SMD₁
6 0.33) evaluations were included as outcomes for sensitivity analysis. Other
7 meta-analyses assessing studies on anxiety and depression^{11,16,59,60} report that
8 effect size seems to diminish over time. Yet, a recent meta-analysis of
9 studies on the prevention of depression found no association between effect
10 size and follow-up time.⁶¹ Regarding the risk of bias, a previous meta-
11 analysis did not ~~found~~ find any statistically significant association between
12 risk of bias and effect size.¹³

13 A tendency was observed ~~in~~ for SMDs to be higher in selective
14 prevention, followed by indicated and universal prevention, although
15 differences were not statistically significant even when adjustment for
16 confounding bias was not performed. Some previous meta-analyses have not
17 found any association between type of prevention and effect size^{11,12,16};
18 however, a 1 meta-analysis found that selective and indicated interventions
19 had a greater effect size than universal prevention,¹³ whereas another meta-
20 analysis reported that universal prevention was more effective.¹⁰

1 As in the rest of the meta-analyses concerning the prevention of
2 anxiety,^{10-13,16} most of the interventions included in our study had a
3 cognitive-behavioral orientation (31 comparisons; SMD, 0.25); the
4 remaining ~~six~~ 6 comparisons had other orientations and tended to have a
5 greater ~~effect~~ response (SMD, 0.52), although it was not statistically
6 significant. Therefore, no conclusions can be drawn about orientation.

7 **Conclusions**

8 The pooled effect size obtained for ~~the~~ prevention of anxiety² is ~~rather~~
9 modest ~~as~~ compared ~~to~~ with the sizes observed in treatments for anxiety
10 disorders.⁶² Although the preventive fraction that derived from the pooled
11 effect size that we obtained (OR, 0.57), **«DT18: 43%»** reduction in the
12 incidence of anxiety, was higher than those found in other meta-analyses,¹¹⁻
13 ^{13,59-61} future studies should strive to further develop and test new prevention
14 interventions with greater effect sizes. Yet, from the perspective of public
15 health, small effects on prevention could have a high impact, thereby
16 improving quality of life and reducing costs. By way of illustration,
17 prevention programs reaching a large population through extensive school²⁸
18 and primary care programs³⁰ or information and communication
19 technologies can have a large cumulative effect.⁶⁴ From this point of view,

1 our results suggest that programs for the prevention of anxiety should be
2 implemented. Nevertheless, there are some aspects that are not well
3 understood and should be further investigated. There are ~~very~~ few studies
4 that assess~~ing~~ the cost-effectiveness and cost-utility of programs for the
5 prevention of anxiety.^{58,65} In addition, long-term RCTs with larger samples
6 and low risk of bias comparing different programs and strategies for the
7 prevention of anxiety are needed.

8 **Article Information**

9 **Accepted for Publication:** June 29, 2017.

10 **Corresponding Author:** Patricia Moreno-Peral, PhD, «DT19: Unidad de
11 Investigación, Distrito de Atención Primaria Málaga-Guadalhorce, _____
12 »C/Sevilla 23, 3ª Planta, 29009 Málaga, Spain
13 (predictmalaga@hotmail.com).

14 **Author Contributions:** Drs Moreno-Peral and Bellón had full access to all
15 the data in the study and take responsibility for the integrity of the data and
16 the accuracy of the data analysis.

17 *Study concept and design:* Moreno-Peral, Conejo-Cerón, Rubio-Valera,
18 Fernandez, Luna del Castillo, Bellón.

1 *Acquisition, analysis, or interpretation of data:* Moreno-Peral, Conejo-
2 Cerón, Rubio-Valera, Fernandez, Navas-Campaña, Rodríguez-Morejón,
3 Motrico, Rigabert, Martín-Pérez, Rodríguez-Bayón, Ballesta-Rodríguez,
4 Luciano, Bellón.

5 *Drafting of the manuscript:* Moreno-Peral, Bellón.

6 *Critical revision of the manuscript for important intellectual content:* All
7 authors.

8 *Statistical analysis:* Moreno-Peral, Conejo-Cerón, Luna del Castillo, Bellón.

9 *Obtained funding:* Bellón.

10 *Administrative, technical, or material support:* Moreno-Peral.

11 *Study supervision:* Rubio-Valera, Fernandez, Luna del Castillo, Bellón.

12 **Conflict of Interest Disclosures:** None reported.

13 **Funding/Support:** This study was supported by the Spanish Ministry of
14 Health, the Institute of Health Carlos III, and ~~the~~European Regional
15 Development Fund Una manera de hacer Europa (~~grant FIS reference:~~
16 PI12/02755) and the Andalusian Council of Health (~~grant reference:~~
17 0583/2012); as well as the Prevention and Health Promotion Research
18 Network ~~‘(redIAPP)’~~² (RD16/0007), ~~the~~‘PRISMA group’²
19 ~~(RD16/0007/0012)~~, and ~~the~~‘SAMSERAP group’² (RD16/0007/0010). ~~The~~

1 ~~next to last author (JVL)~~ [Dr Luciano](#) has a “Miguel Servet” research
2 contract from the Institute of Health Carlos III (~~ISCH~~; CP14/00087).

3 **Role of the Funder/Sponsor:** The funding organizations had no role in the
4 design and conduct of the study; collection, management, analysis, and
5 interpretation of the data; preparation, review, or approval of the manuscript;
6 and decision to submit the manuscript for publication.

7 **Additional Contributions:** ~~The authors thank~~ «DT20: [The Primary Care](#)
8 [District of Málaga provided](#) ~~for their~~ support.» ~~We also thank~~ [The Institute](#)
9 of Health Carlos III (~~ISCH~~), the European Regional Development Fund, the
10 Andalusian Council of Health, the Biomedical Research Institute of Málaga
11 (~~IBIMA~~), and the Prevention and ~~Health Promotion Research Network~~
12 (~~redIAPP~~) ~~for their economic and~~ [provided](#) logistical support.

13 **References**

14 1. Steel Z, Marnane C, Iranpour C, et al. The global
15 prevalence of common mental disorders: a systematic
16 review and meta-analysis 1980-2013. *Int J Epidemiol.*
17 2014;43(2):476-493. [Medline:24648481](#)

- 1 2. Vos T, Allen C, Arora M, et al; GBD 2015 Disease and
2 Injury Incidence and Prevalence Collaborators. Global,
3 regional, and national incidence, prevalence, and years
4 lived with disability for 310 diseases and injuries, 1990-
5 2015: a systematic analysis for the Global Burden of
6 Disease Study 2015. *Lancet*. 2016;388(10053):1545-
7 1602. [Medline:27733282](#)
- 8 3. Whiteford HA, Degenhardt L, Rehm J, et al. Global burden
9 of disease attributable to mental and substance use
10 disorders: findings from the Global Burden of Disease
11 Study 2010. *Lancet*. 2013;382(9904):1575-1586.
12 [Medline:23993280](#)
- 13 4. Acarturk C, Cuijpers P, van Straten A, de Graaf R.
14 Psychological treatment of social anxiety disorder: a
15 meta-analysis. *Psychol Med*. 2009;39(2):241-254.
16 [Medline:18507874](#)
- 17 5. Cuijpers P, Sijbrandij M, Koole S, Huibers M, Berking M,
18 Andersson G. Psychological treatment of generalized

- 1 anxiety disorder: a meta-analysis. *Clin Psychol Rev.*
2 2014;34(2):130-140. [Medline:24487344](#)
- 3 6. Sánchez-Meca J, Rosa-Alcázar AI, Marín-Martínez F,
4 Gómez-Conesa A. Psychological treatment of panic
5 disorder with or without agoraphobia: a meta-analysis.
6 *Clin Psychol Rev.* 2010;30(1):37-50.
7 [Medline:19775792](#)
- 8 7. Fernández A, Haro JM, Martínez-Alonso M, et al.
9 Treatment adequacy for anxiety and depressive
10 disorders in six European countries. *Br J Psychiatry.*
11 2007;190:172-173. [Medline:17267936](#)
- 12 8. Andrews G, Issakidis C, Sanderson K, Corry J, Lapsley H.
13 Utilising survey data to inform public policy:
14 comparison of the cost-effectiveness of treatment of
15 ten mental disorders. *Br J Psychiatry.* 2004;184:526-
16 533. [Medline:15172947](#)
- 17 9. Neil AL, Christensen H. Efficacy and effectiveness of
18 school-based prevention and early intervention

- 1 programs for anxiety. *Clin Psychol Rev.*
2 2009;29(3):208-215. [Medline:19232805](#)
- 3 10. Stockings EA, Degenhardt L, Dobbins T, et al. Preventing
4 depression and anxiety in young people: a review of
5 the joint efficacy of universal, selective and indicated
6 prevention. *Psychol Med.* 2016;46(1):11-26.
7 [Medline:26315536](#)
- 8 11. Werner-Seidler A, Perry Y, Calear AL, Newby JM,
9 Christensen H. School-based depression and anxiety
10 prevention programs for young people: a systematic
11 review and meta-analysis. *Clin Psychol Rev.*
12 2017;51:30-47. [Medline:27821267](#)
- 13 12. Fisak BJ Jr, Richard D, Mann A. The prevention of child
14 and adolescent anxiety: a meta-analytic review. *Prev*
15 *Sci.* 2011;12(3):255-268. [Medline:21437675](#)
- 16 «**WH21:** »13. Teubert D, Piquart M. A meta-analytic
17 review on the prevention of symptoms of anxiety in
18 children and adolescents. *J Anxiety Disord.*
19 2011;25(8):1046-1059.

- 1 14. Forneris CA, Gartlehner G, Brownley KA, et al.
2 Interventions to prevent post-traumatic stress disorder:
3 a systematic review. *Am J Prev Med*. 2013;44(6):635-
4 650. [Medline:23683982](#)
- 5 15. Wessely S, Rose S, Bisson J. Brief psychological
6 interventions ("debriefing") for trauma-related
7 symptoms and the prevention of post traumatic stress
8 disorder. *Cochrane Database Syst Rev*.
9 2000;(2):CD000560. [Medline:10796724](#)
- 10 16. Zalta AK. A meta-analysis of anxiety symptom
11 prevention with cognitive-behavioral interventions. *J*
12 *Anxiety Disord*. 2011;25(5):749-760.
13 [Medline:21698842](#)
- 14 17. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA
15 Group. Preferred reporting items for systematic reviews
16 and meta-analyses: the PRISMA statement. *BMJ*.
17 2009;339:b2535. [Medline:19622551](#)

- 1 18. Piantadosi S. *Clinical Trials: A Methodological*
2 *Perspective*. 2nd ed. Somerset, New Jersey: John Wiley
3 & Sons; 2005.
- 4 19. Kearns MC, Ressler KJ, Zatzick D, Rothbaum BO. Early
5 interventions for PTSD: a review. *Depress Anxiety*.
6 2012;29(10):833-842. [Medline:22941845](#)
- 7 20. Fleiss JL. *Statistical Methods for Rates and Proportions*.
8 2nd ed. New York, NY: John Wiley; 1981.
- 9 21. Higgins JPT, Green S, eds. Cochrane Handbook for
10 Systematic Reviews of Interventions. Version 5.1.0.
11 <http://handbook.cochrane.org/>. Updated March 2011.
12 Accessed May 23, 2017.
- 13 22. Fleiss JL. *The design and Analysis of Clinical*
14 *Experiments*. New York, NY: John Wiley & Sons; 1986.
- 15 23. Cohen J. *Statistical Power Analysis for the Behavioral*
16 *Sciences*. 2nd ed. Hillsdale, NJ: Erlbaum; 1988.
- 17 24. Cates C. Multiple-arm trial data: using a corrected
18 standard error for GIV analyses. Cochrane Colloquium.
19 <https://abstracts.cochrane.org/2015-vienna/multiple->

- 1 [arm-trial-data-using-corrected-standard-error-giv-](#)
2 [analyses](#); Published 2015. Accessed May 1, 2017.
- 3 25. Duval S, Tweedie R. Trim and fill: a simple funnel-plot-
4 based method of testing and adjusting for publication
5 bias in meta-analysis. *Biometrics*. 2000;56(2):455-463.
6 [Medline:10877304](#)
- 7 26. Knapp G, Hartung J. Improved tests for a random effects
8 meta-regression with a single covariate. *Stat Med*.
9 2003;22(17):2693-2710. [Medline:12939780](#)
- 10 27. Higgins JPT, Thompson SG. Controlling the risk of
11 spurious findings from meta-regression. *Stat Med*.
12 2004;23(11):1663-1682. [Medline:15160401](#)
- 13 28. Aune T, Stiles TC. Universal-based prevention of
14 syndromal and subsyndromal social anxiety: a
15 randomized controlled study. *J Consult Clin Psychol*.
16 2009;77(5):867-879. [Medline:19803567](#)
- 17 29. Balle M, Tortella-Feliu M. Efficacy of a brief school-based
18 program for selective prevention of childhood anxiety.

1 *Anxiety Stress Coping*. 2010;23(1):71-85.

2 [Medline:19326270](#)

3 30. Bellón JA, Conejo-Cerón S, Moreno-Peral P, et al.

4 Intervention to prevent major depression in primary
5 care: a cluster-randomized trial. *Ann Intern Med*.

6 2016;164(10):656-665. [Medline:27019334](#)

7 31. Bouchard S, Gervais J, Gagnier N, Loranger C.

8 Evaluation of a primary prevention program for anxiety
9 disorders using story books with children aged 9-

10 12 years. *J Prim Prev*. 2013;34(5):345-358.

11 [Medline:23943134](#)

12 32. Christensen H, Batterham P, Mackinnon A, et al.

13 Prevention of generalized anxiety disorder using a web
14 intervention, iChill: randomized controlled trial. *J Med*

15 *Internet Res*. 2014;16(9):e199. [Medline:25270886](#)

16 «**WH22:** » 33. Cukrowicz KC, Joiner TE Jr. Computer-based

17 intervention for anxious and depressive symptoms in a
18 non-clinical population. *Cognit Ther Res*.

19 2007;31(5):677-693.

- 1 34. Dadds MR, Spence SH, Holland DE, Barrett PM, Laurens
2 KR. Prevention and early intervention for anxiety
3 disorders: a controlled trial. *J Consult Clin Psychol.*
4 1997;65(4):627-635. [Medline:9256564](#)
- 5 35. Dozeman E, van Schaik DJ, van Marwijk HW, Stek ML,
6 Beekman AT, van der Horst HE. Feasibility and
7 effectiveness of activity-scheduling as a guided self-
8 help intervention for the prevention of depression and
9 anxiety in residents in homes for the elderly: a
10 pragmatic randomized controlled trial. *Int*
11 *Psychogeriatr.* 2011;23(6):969-978. [Medline:21338550](#)
- 12 36. Dozeman E, van Marwijk HW, van Schaik DJ, et al.
13 Contradictory effects for prevention of depression and
14 anxiety in residents in homes for the elderly: a
15 pragmatic randomized controlled trial. *Int*
16 *Psychogeriatr.* 2012;24(8):1242-1251.
17 [Medline:22436082](#)
- 18 37. Feldner MT, Zvolensky MJ, Babson K, Leen-Feldner EW,
19 Schmidt NB. An integrated approach to panic

- 1 prevention targeting the empirically supported risk
2 factors of smoking and anxiety sensitivity: theoretical
3 basis and evidence from a pilot project evaluating
4 feasibility and short-term efficacy. *J Anxiety Disord.*
5 2008;22(7):1227-1243. [Medline:18281190](#)
- 6 38. Fledderus M, Bohlmeijer ET, Pieterse ME, Schreurs KM.
7 Acceptance and commitment therapy as guided self-
8 help for psychological distress and positive mental
9 health: a randomized controlled trial. *Psychol Med.*
10 2012;42(3):485-495. [Medline:21740624](#)
- 11 «**WH23:** »39. Gallegos J, Linan-Thompsonb S, Starkb K,
12 Ruvalcabac N. Preventing childhood anxiety and
13 depression: testing the effectiveness of a school-based
14 program in Mexico. *Psicol Educ.* 2013;19(1):37-44.
- 15 40. García-Campayo J, Arevalo E, Claraco LM, Alda M, Lopez
16 del Hoyo Y. A prevention programme for somatoform
17 disorders is effective for affective disorders. *J Affect*
18 *Disord.* 2010;122(1-2):124-132. [Medline:19619900](#)

- 1 «**WH24:** »41. Gardenswartz CA, Craske MG. Prevention of
2 panic disorder. *Behav Ther.* 2001;32:725-737.
- 3 42. Ginsburg GS, Drake KL, Tein JY, Teetsel R, Riddle MA.
4 Preventing onset of anxiety disorders in offspring of
5 anxious parents: a randomized controlled trial of a
6 family-based intervention. *Am J Psychiatry.*
7 2015;172(12):1207-1214. [Medline:26404420](#)
- 8 43. Ginsburg GS. The Child Anxiety Prevention Study:
9 intervention model and primary outcomes. *J Consult*
10 *Clin Psychol.* 2009;77(3):580-587. [Medline:19485597](#)
- 11 44. Joling KJ, van Marwijk HW, Smit F, et al. Does a family
12 meetings intervention prevent depression and anxiety
13 in family caregivers of dementia patients? a
14 randomized trial. *PLoS One.* 2012;7(1):e30936.
15 [Medline:22303473](#)
- 16 45. Li C, Chu F, Wang H, Wang XP. Efficacy of Williams
17 LifeSkills training for improving psychological health: a
18 pilot comparison study of Chinese medical students.

1 *Asia Pac Psychiatry*. 2014;6(2):161-169.

2 [Medline:23857943](#)

3 46. Livermore N, Sharpe L, McKenzie D. Prevention of panic
4 attacks and panic disorder in COPD. *Eur Respir J*.

5 2010;35(3):557-563. [Medline:19741029](#)

6 «**WH25:** »47. Lock S, Barrett PM. A longitudinal study of

7 developmental differences in universal preventive
8 intervention for child anxiety. *Behav Change*.

9 2003;20(4):183-199.

10 48. Mall AK, Mehl A, Kiko S, et al. Evaluation of a DVD-

11 based self-help program in highly socially anxious

12 individuals—pilot study. *Behav Ther*. 2011;42(3):439-

13 448. [Medline:21658526](#)

14 49. Pitceathly C, Maguire P, Fletcher I, Parle M, Tomenson B,

15 Creed F. Can a brief psychological intervention prevent
16 anxiety or depressive disorders in cancer patients? a

17 randomised controlled trial. *Ann Oncol*.

18 2009;20(5):928-934. [Medline:19126633](#)

- 1 50. Rooney R, Hassan S, Kane R, Roberts CM, Nesa M.
2 Reducing depression in 9-10 year old children in low
3 SES schools: a longitudinal universal randomized
4 controlled trial. *Behav Res Ther.* 2013;51(12):845-854.
5 [Medline:24185214](#)
- 6 51. Schmidt NB, Eggleston AM, Woolaway-Bickel K,
7 Fitzpatrick KK, Vasey MW, Richey JA. Anxiety
8 Sensitivity Amelioration Training (ASAT): a longitudinal
9 primary prevention program targeting cognitive
10 vulnerability. *J Anxiety Disord.* 2007;21(3):302-319.
11 [Medline:16889931](#)
- 12 52. Timpano KR, Abramowitz JS, Mahaffey BL, Mitchell MA,
13 Schmidt NB. Efficacy of a prevention program for
14 postpartum obsessive-compulsive symptoms. *J*
15 *Psychiatr Res.* 2011;45(11):1511-1517.
16 [Medline:21764404](#)
- 17 53. Topper M, Emmelkamp PM, Watkins E, Ehring T.
18 Prevention of anxiety disorders and depression by
19 targeting excessive worry and rumination in

1 adolescents and young adults: A randomized controlled
2 trial. *Behav Res Ther.* 2017;90:123-136.

3 [Medline:28049069](#)

4 54. van der Aa HP, van Rens GH, Comijs HC, et al. Stepped
5 care for depression and anxiety in visually impaired
6 older adults: multicentre randomised controlled trial.
7 *BMJ.* 2015;351:h6127. [Medline:26597263](#)

8 55. van't Veer-Tazelaar PJ, van Marwijk HW, van Oppen P,
9 et al. Stepped-care prevention of anxiety and
10 depression in late life: a randomized controlled trial.
11 *Arch Gen Psychiatry.* 2009;66(3):297-304.

12 [Medline:19255379](#)

13 56. van't Veer-Tazelaar PJ, van Marwijk HW, van Oppen P,
14 et al. Prevention of late-life anxiety and depression has
15 sustained effects over 24 months: a pragmatic
16 randomized trial. *Am J Geriatr Psychiatry.*

17 2011;19(3):230-239. [Medline:21425519](#)

18 57. Zhang DX, Lewis G, Araya R, et al. Prevention of anxiety
19 and depression in Chinese: a randomized clinical trial

1 testing the effectiveness of a stepped care program in
2 primary care. *J Affect Disord.* 2014;169:212-220.

3 [Medline:25216464](#)

4 58. Simon E, Dirksen C, Bögels S, Bodden D. Cost-
5 effectiveness of child-focused and parent-focused
6 interventions in a child anxiety prevention program. *J*
7 *Anxiety Disord.* 2012;26(2):287-296.

8 [Medline:22245700](#)

9 59. Cuijpers P, van Straten A, Smit F, Mihalopoulos C,
10 Beekman A. Preventing the onset of depressive
11 disorders: a meta-analytic review of psychological
12 interventions. *Am J Psychiatry.* 2008;165(10):1272-
13 1280. [Medline:18765483](#)

14 60. van Zoonen K, Buntrock C, Ebert DD, et al. Preventing
15 the onset of major depressive disorder: a meta-analytic
16 review of psychological interventions. *Int J Epidemiol.*
17 2014;43(2):318-329. [Medline:24760873](#)

18 61. Conejo-Cerón S, Moreno-Peral P, Rodríguez-Morejón A,
19 et al. Effectiveness of psychological and/or educational

1 interventions to prevent depression in primary care: a
2 systematic review and meta analysis. *Ann Fam Med*.
3 2017;15(3):262-271. [Medline:28483893](#)

4 62. Cuijpers P, Cristea IA, Karyotaki E, Reijnders M, Huibers
5 MJH. How effective are cognitive behavior therapies for
6 major depression and anxiety disorders? a meta-
7 analytic update of the evidence. *World Psychiatry*.
8 2016;15(3):245-258. [Medline:27717254](#)

9 63. Furukawa TA, Noma H, Caldwell DM, et al. Waiting list
10 may be a nocebo condition in psychotherapy trials: a
11 contribution from network meta-analysis. *Acta*
12 *Psychiatr Scand*. 2014;130(3):181-192.
13 [Medline:24697518](#)

14 64. Powell J, Hamborg T, Stallard N, et al. Effectiveness of a
15 web-based cognitive-behavioral tool to improve mental
16 well-being in the general population: randomized
17 controlled trial. *J Med Internet Res*. 2012;15(1):e2.
18 [Medline:23302475](#)

1 65. Mihalopoulos C, Vos T, Rapee RM, et al. The population
2 cost-effectiveness of a parenting intervention designed
3 to prevent anxiety disorders in children. *J Child Psychol*
4 *Psychiatry*. 2015;56(9):1026-1033. [Medline:26111550](#)

5 «DT26: **Figure** »1. The PRISMA Flowchart of the [Randomized](#)

6 [Clinical Trials](#) (RCTs) Included

7 «DT27: **XX**»

8 **Figure 2. Forest Plot of Comparison:** Intervention vs Control Group

9 [Comparison](#)

10 Random effects model. AC indicates active website; [ACE, active](#)
11 [website with email; ACP, active website with telephone;](#) C, control
12 website; CP, control website with telephone; ~~ACP, active website~~
13 ~~with telephone; ACE, active website with email; EES, acceptance and~~
14 ~~commitment therapy with extensive email support; MES, acceptance~~
15 ~~and commitment therapy with minimal email support;~~ GI, group
16 intervention; II, internet intervention; [and SMD, standardized mean](#)
17 [difference](#).

1 Table 1. Effectiveness of Psychological and/or Educational
 2 Interventions to Prevent Anxiety

Primary Analysis	No. of Participants	SMD (95% CI)	P Value	I^2 «DT28: (95% CI)»
Effectiveness to prevent anxiety	36	-0.31 05 (-0.40 0 to -0.21 09)	<.001	61.1% (44% to 73%)
Sensitivity analyses				
At first evaluation	36	-0.29 4 (-0.39 88 to -0.20 0)	<.001	61.8% (45% to 73%)
At last evaluation	36	-0.33 4 (-0.44 39 to -0.23 0)	<.001	67.2% (54% to 77%)
Fixed effects	36	-0.23 3 (-0.28 4 to -0.18 2)	<.001	61.1% (44% to 73%)
Hedges <i>g</i>	36	-0.30 3 (-0.40 398 to -0.21 08)	<.001	61.0% (44% to 73%)
Fledderus et al, ³⁸ 2012 excluded ^a	34	-0.25 47 (-0.33 1 to -0.16 3)	<.001	45.6% (19% to 64%)
RCTs <u>with</u> anxiety as a secondary outcome excluded	32	-0.24 1 (-0.33 0 to -0.15 2)	<.001	42.5% (12% to 62%)

3 Abbreviations: RCTs, randomized ~~control~~-clinical trials; SMD, standardized
 4 mean difference.

5 ^aThe RCT that most increased ~~ds~~ heterogeneity.

1 Table 2. Meta-Regression

Model ^a	«DT29: β » (95% CI) ^b	P Value	«DT30: P Value» (95% CI) ^c
Sample size (lg) ^d	0.1547 (0.062 to 0.23)2	.001	.011 (0.001 to .013)
Risk of bias (lg) ^d	-0.091 (-0.270 to 0.0988)	.31	.867 (0.862 to 0.871)
Standardized interview (outcome)	0.170 (-0.012 to 0.351)	.07	.354 (0.3547 to 0.360)
Waiting list (comparator)	-0.332 (-0.554 to -0.11)09	.005	.031 (0.0329 to 0.034)
Family physician (provider/caregiver)	-0.30299 (-0.6108 to 0.01)0	.06	.3435 (0.3328 to 0.341)

2 «DT31: ^aModel $F_{5,30} = 9.31$; $P < .0001$; I^2 residual, 14.74%; \gg adjusted $R^2 =$
3 99.659%.

4 ^bKnapp and Hartung method for estimation of standard error SE and
5 confidence intervals 95% CIs.

6 ^cHiggins and Thompson permutation test, Monte Carlo approach (20_000
7 permutations).

8 «DT32: ^dLogarithmic transformation of the sample size (S-K test for
9 normality: $\chi^2_2 = 4.11$; $P = .13282$) and risk of bias (S-K test for normality:
10 $\chi^2_2 = 1.99$; $P = .37689$).»

11
12 Supplement. **eAppendix.** Search Strategies

13 **eTable 1.** Characteristics of 29 Randomized Clinical Trials Included to

14 Prevent Anxiety

15 **eTable 2.** Risk of Bias of 29 Randomized Clinical Trials Included to Prevent

16 Anxiety

17 **eTable 3.** Data Used to Calculate SM

1 **eTable 4.** Subgroup Analysis of Effectiveness of Psychological and/or

2 Educational Interventions to Prevent Anxiety

3 **eFigure 1.** Funnel Plot

4 **eFigure 2.** Normal Probability Plot of Standardized Shrunken Residuals

5

6

7

8